Perspektivy primeneniya kapsul vinorelbina v sovremennoy onkologii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Application of oral vinorelbine (OV) in clinical practice extends the possibility of high effective and safe chemotherapy of malignant tumors. The use of OV seems promising in stage IIIb-IV non-small cell lung cancer, at the phase of maintenance treatment and as a component of adjuvant chemoradiation therapy. In breast cancer, OV can be administered as monotherapy or in combination. Also, its use is possible in first-line treatment of HER2 positive metastatic breast cancer in combination with an anti-HER2 agents. Vinorelbine is effective and safe in elderly patients in case of regular medical monitoring.

Full Text

Restricted Access

References

  1. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G., Senac I., Puozzo C. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann. Oncol. 2001;12:1643-49.
  2. Jensen L., Osterlind K., Rytter C. Randomized cross-over study of patient preference for oral or intrave nous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62:85-91.
  3. Gebbia V., Galetta D., Lorusso V., Caruso M., Verderame F., Pezzella G., Borsellino N., Durini E., Valenza R., Agostara B., Colucci G. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced nonsmall cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. Lung Cancer. 2008;61:369-77.
  4. Zhang L., Jianhua C., Huang C., et al. Open-label, randomized multicentre, phase II trial of Oral vinorelbine (NVBo) or intravenous vinorelbine (NVBiv) with cisplatin (CDDP) in patients (pts) with advanced Non Small Cell Lung Cancer (NSCLC): A Chinese experience (CA225 study). IASLC. P3.10. Poster Session 3, 2011.
  5. Reinmuth N., Meyer A., Hartwigsen D., Schaeper C., Huebner G.,Skock-Lober R., Bier A., Gerecke U., Held C.P., Reck M. Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer. 2014;83:363-68.
  6. Jassem J., Ramlau R., Karnicka-Mfodkowska H., Krawczyk K., Krzakowski M., Zatloukal P., Lemarie E.,Hartmann W., NovakovaL, O'Brien M., Depierr A. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann. Oncol. 2001;12:1375-81.
  7. Leong S., Toh C., Lim W., LinX, Tan S.B., Poon D., Tay M.H., Foo K.F, Ho J, Tan E.H. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J. Thorac. Oncol 2007;2(3):230-36.
  8. Karampeazis A., Vamvakas L., Agelidou A., Kentepozidis N., Chainis K., Chandrinos V., Vardakis N., Pallis A.G., Christophyllakis C., Georgoulias V. Docetaxel vs. Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: A Hellenic Oncology Research Group Randomized Phase III Study. Clin. Lung Cancer. 2011;12:55-60.
  9. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., Barbera S., Ferrau F., Piazza E., Rosetti F., Clerici M., Bertetto O., Robbiati S.F., Frontini L., Sacco C., Castiglione F., Favaretto A., Novello S., Migliorino M.R., Gasparini G., Galetta D., Iaffaioli R.V., Gebbia V. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl. Cancer Inst. 2003;95(5):362-72.
  10. DeLena M., Ramlau R., Hansen O., Lorusso V., Wagner L., Barni S., Cristovao M.M., Huber R., Alberola V., Mitrovic M., Colin C., Gasmi J. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer. 2005;48:129-35.
  11. Abratt R., Macha H., Del Barco S., et al. Vinorelbine (NVB) oral (NVBo) in combination with carboplatin (CBDCA) followed by maintenance therapy with single agent vinorelbine oral in stage III/IV non-small cell lung cancer (NSCLC): Final results of a multicenter international phase II trial. J. Clin. Oncol. 2006;24( 18S):7126. ASCO Annual Meeting Proceedings.
  12. Reck M., Macha H., Del Barco S., Cornes P., Vaissiere N., Morand M., Riggi M., Abratt R. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single -agent in unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer. 2009;64(3):319-25.
  13. Bennouna J., Havel L., Krzakowski M., Kollmeier J., Gervais R., Dansin E., Serke M., Favaretto A., Szczesna A., Cobo M., Ciuffreda L., Jassem J., Nicolini M., Ramlau R., Amoroso D., Melotti B., Almodovar T., Riggi M., Caux N.R., Vaissiere N., Tan E.H. Oral vinorelbine plus cisplatin as first-line chemotherapy in non squamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).Clin. Lung Cancer. 2014;15(4):258-65.
  14. Sorensen S., Carus A., Meldgaard P. Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. Lung Cancer. 2015;88(2):167-73.
  15. Aapro M., Finek J. Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results. Cancer Treat. Rev. 2012;38:120-26.
  16. Mansour М., Mourad С. Phase II study of single agent oral vinorelbine as first line treatment in patients with HER2 negative metastatic breast cancer. Cancer Chemother. Pharmacol. 2013;72(2):429-35.
  17. Tubiana N., Bougnoux P., Becquart D., Chan A., Conte P.F., Majois F., Espie M., Morand M., Vaissiere N., Villanova G. All-oral combination of vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Br. J. Cancer. 2009;101:232-37.
  18. Campone M., Dobrovolskaya N., Tjulandin S., Chen S.C., Fourie S., Mefti F., Konstantinova M., Lefresne F., Meheust N., Jassem J. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast J. 2013;19(3):240-49.
  19. Lorusso V., Cinieri S., Giampaglia M., Ciccarese M., Tinelli A., Chiuri V., Manca C., Silvestris N., Gasparini G., Colucci G. Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. Breast. 2010;19: 214-48.
  20. Battelli N., Bittoni A., Pagliacci A., Zepponi L., Scartozzi M., Mariotti C., Cascinu S. Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. Tumori. 2011;97:449-53.
  21. Petruzelka L., Ganju V., Becquart D., et al. Phase II study of the combination of oral vinorelbine, capecitabine and trastuzumab in HER2-positive metastatic breast cancer: recent analysis of the results with a median follow-up of 44 months. J. Clin. Oncol. 2010;28:15S (abstract 1077).
  22. Palumbo R., Bernardo A., Strada M., et al. Triple combination of 3-weekly trastuzumab plus oral vinorelbine and capecitabine as first-line treatment in HER2- positive metastatic breast cancer: an active and well-tolerated regimen that allows patient compliance. Eur. J. Cancer. 2009;7(2) (abstract 5081).
  23. Strada M., Palumbo R., Bernardo A., Riccardi A., Teragni C., Poggi G., Frascaroli M., Amatu A., Montagna B., Sottotetti F., Tagliaferri B., Bernardo G. Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2 - Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials. Clin. Breast Cancer. 2012;12(1):30-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies